Zhangzhou Pientzehuang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
Zhangzhou Pientzehuang Pharmaceutical has a total shareholder equity of CN¥14.6B and total debt of CN¥1.1B, which brings its debt-to-equity ratio to 7.3%. Its total assets and total liabilities are CN¥18.0B and CN¥3.4B respectively. Zhangzhou Pientzehuang Pharmaceutical's EBIT is CN¥3.5B making its interest coverage ratio -27.1. It has cash and short-term investments of CN¥3.3B.
Key information
7.3%
Debt to equity ratio
CN¥1.06b
Debt
| Interest coverage ratio | -27.1x |
| Cash | CN¥3.27b |
| Equity | CN¥14.60b |
| Total liabilities | CN¥3.39b |
| Total assets | CN¥17.99b |
Recent financial health updates
These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely
Nov 07
These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely
May 27Recent updates
Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Share Price Could Signal Some Risk
Nov 25These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely
Nov 07Earnings Beat: Zhangzhou Pientzehuang Pharmaceutical., Ltd Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Oct 22Estimating The Intrinsic Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)
Sep 08Earnings Miss: Zhangzhou Pientzehuang Pharmaceutical., Ltd Missed EPS By 39% And Analysts Are Revising Their Forecasts
Aug 20Subdued Growth No Barrier To Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Price
Jul 12These 4 Measures Indicate That Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Is Using Debt Safely
May 27Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Business Is Yet to Catch Up With Its Share Price
Feb 28Financial Position Analysis
Short Term Liabilities: 600436's short term assets (CN¥15.8B) exceed its short term liabilities (CN¥3.1B).
Long Term Liabilities: 600436's short term assets (CN¥15.8B) exceed its long term liabilities (CN¥289.5M).
Debt to Equity History and Analysis
Debt Level: 600436 has more cash than its total debt.
Reducing Debt: 600436's debt to equity ratio has reduced from 12% to 7.3% over the past 5 years.
Debt Coverage: 600436's debt is well covered by operating cash flow (106%).
Interest Coverage: 600436 earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 13:54 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhangzhou Pientzehuang Pharmaceutical., Ltd is covered by 30 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sandra Sun | BofA Global Research |
| Siti Bte Salikin | CFRA Equity Research |
| Shuchang Liu | Changjiang Securities Co. LTD. |